

8th February, 2021

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Sub: Outcome of the Board Meeting

The Board of Directors (Board) of the Company at its meeting held today i.e., 08th February, 2021, inter alia, has taken note and approved the Un-Audited Financial Results (standalone and consolidated) for the third quarter ended 31st December, 2020. The un-audited results along with limited review reports are enclosed herewith as (**Annexure – 1**).

The Board has approved the following:

- In-principally approved further acquisition of 35% stake in its subsidiary namely, Dresen Quimica SAPI de CV (“Dresen”) from Controladora De Servicios Riso S.A.P.I. de C.V. (the “joint venture partner”) for an amount not exceeding USD 13 million (United States Dollar Thirteen Million), subject to regulatory approvals, if necessary and execution of definitive agreement(s) by the Company with the joint venture partner.

Dresen is a joint venture between the Company and Controladora De Servicios Riso S.A.P.I. de C.V. in which the Company currently holds 65% stake.

The Board has authorized Mr. Ashish Dandekar – Managing Director to negotiate and finalize the terms and mechanism of the said acquisition and finalize and execute the necessary agreements/documents with the joint venture partner.

Post completion of the said acquisition, Dresen will become a wholly-owned subsidiary of the Company. The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 (**Annexure 2**).




Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

- Appointment of M/s. P. S. Joglekar & Co., Chartered Accountants as Internal Auditors of the Company. **(Annexure 3).**
- Appointment of M/s. JHR & Associates, Practicing Company Secretaries for conducting secretarial audit for the financial year ending 31st March, 2021 as per the provisions of section 204 of the Companies Act, 2013.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Thanking You,


Encl.: a/a.


Thanking You,
For **Camlin Fine Sciences Limited**



Mandar Godbole
Company Secretary
& Compliance Officer

 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlins.com

 www.camlins.com



Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.

CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

(Rs.in Lakh, except per share data)

PART I		PARTICULARS	STANDALONE						CONSOLIDATED							
			QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED	QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED
			31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020		
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
1	Revenue from operations	16,364.25	14,677.72	15,316.07	43,158.91	44,023.42	57,977.90	29,792.48	25,681.03	27,388.07	86,047.90	75,628.16	1,04,914.84			
2	Other income	141.53	132.54	277.31	373.16	835.66	2,406.44	114.29	128.21	65.11	289.12	142.85	342.84			
3	Total income	16,505.78	14,810.26	15,593.38	43,532.07	44,859.08	60,384.34	29,906.77	25,809.24	27,453.18	86,337.02	75,771.01	1,05,257.68			
4	Expenses															
	Cost of materials consumed	10,615.26	10,580.24	9,976.14	29,416.57	30,040.54	37,741.66	12,415.82	11,598.85	13,458.54	33,968.84	32,853.34	49,970.58			
	Purchase of stock in trade	170.81	152.24	565.75	353.85	1,071.92	1,348.05	2,007.65	1,196.85	858.24	6,752.26	4,935.36	5,346.60			
	Changes in inventories of finished goods/WIP/stock in trade	(1,058.88)	(838.26)	(102.06)	(2,474.12)	(1,250.02)	(205.83)	(1,007.83)	(787.15)	(279.16)	1,032.34	147.01	(1,939.42)			
	Employee benefits expense	1,078.24	933.76	679.65	2,718.35	1,974.96	2,801.12	3,145.61	2,842.74	2,577.96	8,527.30	7,208.32	9,971.26			
	Finance costs	809.87	591.01	693.90	2,261.58	2,130.05	2,806.82	675.07	812.63	754.58	2,542.97	2,789.94	4,312.91			
	Depreciation and amortisation expense	628.07	338.18	263.35	1,272.01	819.70	1,128.21	1,335.55	963.20	840.62	3,246.81	2,367.60	3,280.23			
	Other expenses	3,772.85	3,140.91	2,788.54	9,021.52	7,607.61	10,321.62	8,554.01	7,465.34	7,817.17	22,617.35	20,919.77	28,495.35			
	Total Expenses	16,016.22	14,898.08	14,865.27	42,569.76	42,394.76	55,941.65	27,125.68	24,092.46	26,027.95	78,687.87	71,221.34	99,437.51			
5	Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)	489.56	(87.82)	728.11	962.31	2,464.32	4,442.69	2,781.09	1,716.78	1,425.23	7,649.15	4,549.67	5,820.17			
6	Exceptional items (Refer note 4)	-	-	-	50.32	314.07	314.07	-	-	-	-	-	-			
7	Profit / (Loss) before share of profit / (loss) of associate (5-6)	489.56	(87.82)	728.11	911.99	2,150.25	4,128.62	2,781.09	1,716.78	1,425.23	7,649.15	4,549.67	5,820.17			
8	Share of profit / (loss) of associate	-	-	-	-	-	-	-	-	-	-	-	(0.09)			
9	Profit / (Loss) before tax (7-8)	489.56	(87.82)	728.11	911.99	2,150.25	4,128.62	2,781.09	1,716.78	1,425.23	7,649.15	4,549.67	5,820.08			
10	Tax Expenses						0.30									
	- Current tax	91.58	(15.49)	130.20	168.03	384.50	750.04	588.84	418.97	625.86	1,853.39	1,673.83	2,488.99			
	- Deferred tax	62.47	29.47	127.55	129.37	347.75	306.45	250.38	331.61	416.63	831.69	97.76	348.01			
11	Profit / (Loss) for the period (9-10)	335.51	(101.80)	470.36	614.59	1,418.00	3,072.13	1,941.87	966.20	382.74	4,964.07	2,778.08	2,983.08			
12	Other comprehensive income															
A	(i) Items that will not be reclassified to profit or loss															
	Remeasurements of defined benefit plans	(7.71)	(15.02)	(36.86)	(16.58)	(85.60)	(44.80)	(7.71)	(15.02)	(36.86)	(16.58)	(85.60)	(44.80)			
	Income tax relating to Items that will not be reclassified to profit or loss	2.69	5.25	8.13	5.79	20.62	15.66	2.69	5.25	8.13	5.79	20.62	15.66			
B	(i) Items that will be reclassified to profit or loss															
	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	1,164.01	434.83	466.05	2,058.39	(403.35)	180.70			
	Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	(203.86)	-	150.34	(21.37)			
	Other comprehensive income	(5.02)	(9.77)	(28.73)	(10.79)	(64.98)	(29.14)	1,158.99	425.06	233.46	2,047.60	(317.99)	130.19			
13	Total comprehensive income for the period (11+12)	330.49	(111.57)	441.63	603.80	1,353.02	3,042.99	3,100.86	1,391.26	616.20	7,011.67	2,460.09	3,113.26			
14	Profit / (loss) attributable to:															
	(i) Owners of the Company							1,541.94	589.05	515.62	3,669.81	2,764.65	3,031.86			
	(ii) Non-controlling interests							399.93	377.15	(132.88)	1,294.26	13.43	(48.78)			
15	Other comprehensive income attributable to:															
	(i) Owners of the Company							743.29	386.61	221.45	1,482.57	(330.60)	150.35			
	(ii) Non-controlling interests							415.70	38.45	12.01	565.03	12.61	(20.16)			
	Total comprehensive income attributable to:															
	(i) Owners of the Company							2,285.23	975.66	737.07	5,152.38	2,434.05	3,182.21			
	(ii) Non-controlling interests							815.63	415.60	(120.87)	1,859.29	26.04	(68.94)			
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,274.72	1,212.85	1,212.54	1,274.72	1,212.54	1,212.54	1,274.72	1,212.85	1,212.54	1,274.72	1,212.54	1,212.54			
18	Other Equity						36,467.78						39,101.14			
19	Earnings per Share (EPS) (of Re.1/-each) (not annualised)															
	Basic (Rs.)	0.27	(0.08)	0.39	0.50	1.17	2.53	1.26	0.49	0.43	3.00	2.28	2.50			
	Diluted (Rs.)	0.25	(0.08)	0.39	0.46	1.17	2.53	1.15	0.46	0.42	2.73	2.28	2.50			



Registered Office:

Camlin Fine Sciences Ltd. F/11-1-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 151, India
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

Notes to financial results:

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 08, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Rs. In Lakh.

Particulars	STANDALONE						CONSOLIDATED						
	QUARTER ENDED			NINE MONTHS ENDED			QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED
	31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)	31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)	
Other Income	-	-	173.32	-	521.87	1,825.84	-	-	51.70	-	-	37.36	
Other Expense	245.75	732.14	-	977.25	-	-	192.87	885.15	-	1,399.89	77.42	-	
Total Exchange gain / (loss)	(245.75)	(732.14)	173.32	(977.25)	521.87	1,825.84	(192.87)	(885.15)	51.70	(1,399.89)	(77.42)	37.36	

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Rs. In Lakh.

Particulars	STANDALONE						CONSOLIDATED						
	QUARTER ENDED			NINE MONTHS ENDED			QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED
	31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)	31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)	
Exchange gain	71.58	198.98	-	249.99	-	-	327.20	317.92	73.04	665.40	-	-	
Exchange loss	-	-	93.92	-	322.61	389.68	-	-	-	-	277.88	959.94	
Total Exchange gain / (loss)	71.58	198.98	(93.92)	249.99	(322.61)	(389.68)	327.20	317.92	73.04	665.40	(277.88)	(959.94)	

- Exceptional item pertains to impairment of investment in CFS International Trading (Shanghai) Limited of Rs. 50.32 lakhs.
- On September 17, 2020, Company had received 33% subscription against preferential issue of 35,500,000 warrants amounting to INR 5,610.31 lakh. Subscription price of each warrant is INR 47.89 and each warrant is convertible into one equity share each. The Company received application for conversion of 6,150,000 warrants during the quarter. The balance amount receivable towards such warrants, equivalent to 67% of subscription price amounting to INR 1,973.31 lakhs has been received by the Company. On November 24, 2020, the Company has allotted 6,150,000 equity shares of Re.1 each respectively at a premium of Rs. 46.89 per equity share upon conversion of warrants.
- During the nine months ended December 31, 2020, the Company has issued and allotted 67,975 equity shares of Re.1 each respectively at a premium of Rs. 49 per equity share aggregating to INR 33.98 lakh under Employees Stock Option Scheme, 2018. No employee stock options under ESOP -2018 have lapsed during the quarter and nine months ended December 31, 2020.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company is in process of evaluating the financial impact, if any.
- Company / Group has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of the financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company / Group, has used internal and external sources of information on the expected future performance of the Company and the Group, its ability to meet its liabilities and in assessing the recoverability and carrying values of its assets. There is no material change in the internal control environment in the group. The impact of COVID-19 on the Group's financial statements may differ from that estimated as at the date of approval of these consolidated financial statements.
- The Company's operations constitute a single business segment in Fine Chemicals.
- Figures for previous periods have been regrouped/rearranged wherever necessary.

Place: Lonavala
Date: February 08, 2021



FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
Managing Director

KALYANIWALLA & MISTRY LLP


CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited,
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East).

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Camlin Fine Sciences Limited ("the Company"), for the quarter ended December 31, 2020 and for the period from April 1, 2020 to December 31, 2020 ("the Statement"). This statement which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166



FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 21127355AAAABT2376
Place: Mumbai
Date: February 8, 2021

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East), Mumbai-400096

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Camlin Fine Sciences Limited (the "Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and an associate for the quarter ended December 31, 2020 and for the period from April 01, 2020 to December 31, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i. Camlin Fine Sciences Limited
 - ii. CFS Europe S.p.A.
 - iii. CFS Do Brasil Importacao E Exportacao De Aditivos Alimenticios LTDA
 - iv. Solentus North America Inc
 - v. CFS North America LLC
 - vi. CFS International Trading (Shanghai) Ltd (upto September 14, 2020)
 - vii. Dresen Quimica, S.A.P.I. de C.V.
 - viii. Inovel, S.A.S.
 - ix. Industrias Petrotec De Mexico S.A De C.V.



- x. Nuvel, S.A.C.
 - xi. Britec, S.A.
 - xii. Grinel, S.R.L.
 - xiii. Chemolutions Chemicals Ltd.
 - xiv. CFS Wanglong Flavours (Ningbo) Co. Ltd.
 - xv. CFS Argentina S.A.
 - xvi. CFS Chile S.p.A
 - xvii. CFS Pahang Asia Pte Ltd.
 - xviii. Fine Lifestyle Brands Ltd.
5. Based on our review and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of ten subsidiaries incorporated outside India and a subsidiary in India included in the Statement, whose interim financial results reflect total revenues of Rs. 22,515.77 lakhs and Rs. 70,608.81, total net profit after tax of Rs. 1,711.47 lakhs and Rs. 4,790.86 lakhs and total comprehensive income of Rs. 2,996.74 lakhs and Rs. 6,833.19 lakhs for the quarter and for the period from April 01, 2020 to December 31, 2020 respectively. The statement also includes group's share of net profit of Rs. Nil for the quarter and period from April 01, 2020 to December 31, 2020 in respect of an associate company. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

In respect of ten subsidiaries located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective country and which has been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the interim financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to amounts and disclosures included in respect of such subsidiaries located outside India is based on the reports of the other auditors and the conversion adjustments made by the management of the Company and reviewed by us.

Our conclusion on the statement is not modified in respect of the above matter.


7. The Statement includes interim financial results of five subsidiaries incorporated outside India, whose interim financial results reflect total revenues of Rs. 243.68 lakhs and Rs. 740.80 lakhs, total net profit after tax of Rs. 15.85 lakhs and Rs. 47.04 lakhs and total comprehensive income of Rs. 18.58 lakhs and Rs. 68.17 lakhs for the quarter and for the period from April 01, 2020 to December 31, 2020 respectively. These interim financial results of five subsidiaries are not reviewed as of the date of this report and have been included in the interim financial results on the basis of the Unaudited Management Accounts. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.



**KALYANIWALLA
& MISTRY LLP**

Our report on the Statement is not modified in respect of our reliance on the Unaudited Management Accounts and other financial information furnished by the management.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 21127355AAAABU5425
Place: Mumbai
Dated: February 8, 2021**

FOR CAMLIN FINE SCIENCES LIMITED



Ashish S. Dandekar
Managing Director

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020													(Rs.in Lakh)
No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Total Income from Operations	16,364.25	14,677.72	15,316.07	43,158.91	44,023.42	57,977.90	29,792.48	25,681.03	27,388.07	86,047.90	75,628.16	1,04,914.84
2	Net Profit from ordinary activities after tax	335.51	(101.80)	470.36	614.59	1,418.00	3,072.13	1,941.87	966.20	382.74	4,964.07	2,778.08	2,983.08
3	Net Profit for the period after tax and non-controlling interests (after extraordinary items)	-	-	-	-	-	-	1,541.94	589.05	515.62	3,669.81	2,764.65	3,031.86
4	Total Comprehensive Income for the period	330.49	(111.57)	441.63	603.80	1,353.02	3,042.99	3,100.86	1,391.26	616.20	7,011.67	2,460.09	3,113.26
5	Equity Share Capital	1,274.72	1,212.85	1,212.54	1,274.72	1,212.54	1,212.54	1,274.72	1,212.85	1,212.54	1,274.72	1,212.54	1,212.54
6	Other Equity						36,467.78						39,101.14
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)												
	-Basic Rs.	0.27	(0.08)	0.39	0.50	1.17	2.53	1.26	0.49	0.43	3.00	2.28	2.50
	-Diluted Rs.	0.25	(0.08)	0.39	0.46	1.17	2.53	1.15	0.46	0.42	2.73	2.28	2.50

1 The above information is an extract of the detailed format of unaudited results for the quarter and nine months ended December 31, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter and nine months ended December 31, 2020 are available on the Company's website, www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

Place: Lonavala
Date: February 08, 2021

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

Annexure 2

Name of the target entity, details in brief such as size, turnover etc.	Dresen Quimica SAPI de CV ("Dresen") Turnover for Nine Months ended December 31, 2020: INR 203.93 crore.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	No Not applicable
Industry to which the entity being acquired belongs.	Chemical industry
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	The Company already has controlling stake in Dresen and proposes to increase it from 65% to 100%.
Brief details of any governmental or regulatory approvals required for the acquisition.	Not applicable
Indicative time period for completion of the acquisition.	March 31, 2024
Nature of consideration - whether cash consideration or share swap and details of the same.	Cash consideration
Cost of acquisition or the price at which the shares are acquired.	Amount not exceeding USD 13 million (United States Dollar Thirteen Million).
Percentage of shareholding / control acquired and / or number of shares acquired.	35%
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Dresen was incorporated in May 6, 1987. The target entity sells its products directly to feed and food manufacturers, rendering plants, pet food manufacturers and industrial consumers. Dresen has presence in five countries namely, Mexico, Guatemala, Peru, Columbia and Dominican Republic. The turnover of Dresen (combined with its subsidiaries) for the previous 3 years is as follows: F.Y.2019-2020: INR 257.11 crore. F.Y. 2018-19: INR 217.19 crore. F.Y. 2017-18: INR 164.19 crore.

Mang Godbole


Registered Office:
 Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
 CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com


www.camlinfs.com


BRIEF PROFILE OF M/S. P. S. JOGLEKAR & CO

Name of the Firm	M/s. P. S. Joglekar & Co., Chartered Accountants
Address of the Firm	205, Apollo complex Premises CHS Ltd. R. K. Singh Marg, Off Old Nagardas Road, Andheri (East), Mumbai – 400 069.
Name of Proprietor	Prasad S. Joglekar
Firm Registration No	119846W (1999)
Profile	The firm is engaged in providing Audit Services etc.
Term of Appointment	w.e.f. 1 st April, 2021 to 31 st March, 2022




 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com